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Abstract
Background—Patent ductus arteriosus (PDA) is common in extremely premature infants and 
associated with increased morbidity and mortality. Medical management of PDA uses either 
indomethacin or ibuprofen. Despite numerous studies, uncertainty exists as to which drug is safer 
or more effective; we sought to fill this knowledge gap.
Methods—We identified infants <28 weeks gestational age discharged from neonatal intensive 
care units included in the Pediatrix Medical Group Clinical Data Warehouse between 2006 and 
2012 who were treated with indomethacin or ibuprofen between postnatal day 2 and 14. Infants 
treated with both drugs or infants with a congenital malformation were excluded. We used 
multivariable logistic regression to determine the association of indomethacin versus ibuprofen on 
clinical outcomes.
Results—Of 6349 patients who met study criteria, 1177 (19%) received ibuprofen and 5172 
(81%) received indomethacin. The median gestational age was 25 weeks (interquartile range 24–
26), and 2894 (46%) infants were <750 g at birth. On unadjusted analysis, infants who received 
ibuprofen had significantly higher incidences of death prior to discharge, surgical ligation of the 
PDA prior to discharge, death or spontaneous intestinal perforation within 7 days of therapy, death 
or surgical ligation of the PDA prior to discharge, and an elevated creatinine within 7 days of 
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treatment. However, on multivariable analysis, no significant differences in outcomes were 
observed (odds ratio for death/PDA ligation for ibuprofen vs. indomethacin = 1.12 [95% CI 0.91–
1.39]).
Conclusions—We observed similar effectiveness and safety profiles for indomethacin and 
ibuprofen in the medical management of PDA in premature infants.
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1. INTRODUCTION
The ductus arteriosus (DA) is a normal anatomic conduit in the fetus, allowing blood to 
bypass the pulmonary circuit [1]. The DA is kept open while in utero through a combination 
of prostaglandins, nitric oxide, and pressure differentials [2]. After birth, via contracture of 
the smooth muscle within its walls likely secondary to an increase in oxygen tension and a 
decrease in prostaglandins, the DA closes and becomes the ligamentum arteriosum [2]. 
Functional closure of the DA usually occurs within hours of birth in term infants; however, 
in premature infants, the DA frequently fails to close after birth or experiences substantial 
delay in closure [3]. This condition, known as patent ductus arteriosus (PDA) [4], has been 
associated with bronchopulmonary dysplasia (BPD), increased ventilation requirements, 
poor feeding tolerance, and increased mortality in premature infants [5,6].
Since the 1970s, indomethacin, an inhibitor of prostaglandin synthesis, has been used in the 
treatment of PDA [7–9]. However, indomethacin has been associated with adverse events, 
including increased risk of necrotizing enterocolitis and renal insufficiency [10–15]. To find 
a safer alternative to indomethacin, ibuprofen was approved for the treatment of PDA in 
2006 [16]. However, ibuprofen has also recently been linked to adverse events including 
spontaneous intestinal perforation (SIP), leading to uncertainty over which drug has the 
better safety profile [17–19]. Further intensifying this debate, a voluntary recall by the 
supplier of ibuprofen in 2010 forced many clinicians to return to using indomethacin [20].
A number of studies have compared the safety and efficacy of ibuprofen and indomethacin 
[9,21–23]. These studies have consistently demonstrated similar effectiveness between the 2 
drugs, but indomethacin tended to demonstrate a worse side effect profile [21]. Despite the 
available evidence, neonatologists continue to use both drugs for the treatment of PDA [24–
26]. To better assess the risks and benefits of each drug, we performed a retrospective 
review to determine the safety and effectiveness of ibuprofen and indomethacin. We 
hypothesized that there would be no significant differences in effectiveness or safety 
between the 2 drugs.
2. METHODS
2.1. Data Source and Study Population
We obtained data for our study from the Pediatrix Medical Group Clinical Data Warehouse, 
a prospective clinical database that captures information from daily progress notes generated 
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by clinicians on all infants discharged from 165 neonatal intensive care units managed by 
the Pediatrix Medical Group in the United States. We collected information on prenatal 
characteristics, demographics, timing and duration of exposure to ibuprofen or 
indomethacin, and clinical and laboratory diagnoses of interest, as well as clinical outcomes.
We included all inborn infants <28 weeks gestational age (GA) discharged between 2006 to 
2012 who received either indomethacin or ibuprofen and were first exposed to either drug 
from postnatal day 2 to postnatal day 14. We excluded infants exposed to both drugs and 
infants diagnosed with a major congenital anomaly. We excluded infants treated on the first 
2 days of life to eliminate infants receiving prophylaxis for intraventricular hemorrhage.
2.2. Definitions
We identified infants as exposed to indomethacin or ibuprofen and analyzed the first course 
of therapy for each infant. We defined small for gestational age (SGA) as <10th percentile 
for age [27]. As surrogates for severity of illness, we identified exposure to any inotropic 
medication (dopamine, dobutamine, epinephrine, milrinone, and phenylephrine) or systemic 
hydrocortisone, as well as any mechanical ventilator support or need for supplemental 
oxygen (FiO2) on the first day of therapy. We defined renal insufficiency at the onset of 
therapy as any serum creatinine >1 mg/dL on the first day of therapy or up to 2 days prior. 
We identified several outcomes of interest: death prior to discharge, death or PDA requiring 
surgical ligation prior to discharge, SIP within 7 days of start of therapy, death or SIP within 
7 days of start of therapy, death or BPD prior to discharge, serum creatinine >1 mg/dL 
within 7 days of the start of therapy, and the combined outcome of any one of these events. 
BPD was defined as patients who received continuous supplemental oxygen or respiratory 
support from a corrected GA of 36 0/7–36 6/7 weeks.
2.3. Statistical Analysis
The unit of observation for this study was the infant. We used standard summary statistics, 
including medians (interquartile ranges) and counts (percentages), to describe continuous 
and categorical study variables. We described the use of indomethacin and ibuprofen by 
year over the course of the study, as well as variation in the use of the 2 drugs by site. We 
compared the distribution of predictor variables and the outcomes of interest between infants 
exposed to indomethacin versus ibuprofen using Wilcoxon rank sum and chi-square tests of 
association. We used multivariable mixed logistic regression with fixed effects for site to 
evaluate the association between indomethacin and ibuprofen exposure and each outcome of 
interest. We conducted standard model assumptions diagnostics and evaluation for 
collinearity [28]. We first evaluated a model including all plausible predictor variables 
available, including their interactions as covariates. Initial predictors included GA, SGA, 
inotrope use, hydrocortisone use on first day of therapy, creatinine >1 mg/dL, mechanical 
ventilation, supplemental oxygen on first day of therapy, prenatal steroid exposure, 
discharge year, and postnatal age on first day of therapy. We then performed likelihood ratio 
tests to compare the full model to a priori determined reduced models and reported the most 
parsimonious model that fit the data well. A priori reduced models were produced by 
systematically dropping variables that were less likely to be related to the outcome. The final 
multivariable logistic regression model used site as a fixed effect and included the following 
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covariates: GA, SGA status, prenatal steroid exposure, discharge year, postnatal age on the 
first day of therapy and the need for inotropic support, hydrocortisone use, mechanical 
ventilation, supplemental oxygen on the first day of therapy, and baseline creatinine >1 
mg/dL.
We further analyzed trends in the use of indomethacin and ibuprofen over the study period, 
as well as variation by center in the use of each drug following the removal of any site with 
<10 patients during the study period. All statistical analyses were conducted using Stata12 
(College Station, TX). A p<0.05 was defined as statistically significant. This study was 
approved by the institutional review board at the corresponding author’s university.
3. RESULTS
3.1. Study Population
We identified 6349 infants from 165 sites who met our study criteria (Fig. 1); 1177 (19%) 
received ibuprofen and 5172 (81%) received indomethacin. Median GA was 25 weeks 
(interquartile range 24–26, Table 1). Birth weight, SGA status, race/ethnicity, the use of 
antenatal steroids, baseline creatinine >1 mg/dL, requirement of supplemental oxygen, and 
use of hydrocortisone on the first day of therapy were significantly different between the 
ibuprofen and indomethacin groups; however, the absolute differences between groups were 
small.
3.2. Outcomes
The incidences of death prior to discharge (17% vs. 13%, p<0.01), PDA ligation prior to 
discharge (27% vs. 24%, p=0.04), death or PDA ligation prior to discharge (40% vs. 34%, 
p<0.01), death or SIP within 7 days of therapy (18% vs. 14%, p<0.01), and creatinine >1.0 
mg/dL within 7 days of treatment (36% vs. 32%, p<0.01) were significantly higher in the 
ibuprofen group compared with the indomethacin group (Table 2). Following adjustment, no 
statistically significant difference in outcomes remained.
3.3. Temporal Trends and Site-Based Differences
The use of indomethacin decreased from 98% of treated infants in 2006 to 66% of cases in 
2008 before rebounding back to 98% in 2011 (Fig. 2). Following removal of any site with 
<10 cases during the study period, we determined how ibuprofen and indomethacin use 
varied by site (Fig. 3). Among sites with ≥10 infants treated with either ibuprofen or 
indomethacin during the study period, indomethacin use varied between 17% and 100%, 
with 38/125 sites (30%) using only indomethacin.
4. DISCUSSION
We found that exposure to indomethacin or ibuprofen resulted in no significant difference in 
hospital mortality, surgical ligation, SIP, BPD, or renal insufficiency between groups after 
adjusting for baseline severity of illness. Although, historically, indomethacin was the 
treatment of choice for medical closure of PDA, concerns over side effects, especially those 
affecting the gastrointestinal (particularly when used with hydrocortisone) and renal 
systems, led to the increasing use of ibuprofen for this indication [10,12,16,21]. Our findings 
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are consistent with previous studies that also found similar outcomes with regard to 
mortality, surgical ligation, SIP, and BPD [21–23,29].
Our findings, however, did not demonstrate a higher risk of elevated creatinine associated 
with indomethacin as observed in prior studies [21–23,30]. For instance, Van Overmeire et 
al. randomized 148 infants to treatment with indomethacin or ibuprofen and found similar 
efficacy between the 2 groups but a significant increase in oliguria and serum creatinine in 
patients treated with indomethacin compared with ibuprofen [30]. A Cochrane review that 
included 15 studies and 740 infants also found no statistical difference in the effectiveness 
of the 2 medications but did report that there was less evidence of renal insufficiency 
associated with ibuprofen compared with indomethacin [29]. Unfortunately, due to the small 
differences in effectiveness between indomethacin and ibuprofen, a randomized controlled 
trial large enough to detect a difference between the 2 drugs would not be feasible. For 
example, to detect a 3.75% absolute difference observed in death or PDA ligation in our 
adjusted analysis between the 2 groups, 5400 infants would be needed to have 80% power.
In addition, we found that, since its approval by the Food and Drug Administration in 2006, 
ibuprofen has been increasingly used in the medical management of PDA [16]. This is likely 
due to the general notion that ibuprofen had fewer renal-related side effects than 
indomethacin, supported by studies performed in the mid-2000s [21,31]. However, by 2010, 
the use of indomethacin returned to its 2006 level, likely secondary to the voluntary recall of 
2 lots of ibuprofen lysine by Lundbeck Inc. in July 2010, which accounted for the majority 
of the national drug supply at the time [20].
There was also significant variation in the use of the 2 drugs among sites, with the majority 
of sites using a mixture of ibuprofen and indomethacin. Except for the unavailability of 
ibuprofen following the 2010 recall, we are unable to speculate on what factors may have 
influenced the decision to use a specific drug at each site. Interestingly, clinicians appeared 
to use ibuprofen more commonly in infants with an elevated baseline creatinine, likely due 
to concern about the effect of indomethacin on the kidney. Nonetheless, after including 
serum creatinine in our adjusted model, we still did not observe any significant difference in 
post-treatment renal insufficiency between groups.
Although we present the largest retrospective study to date on the use of ibuprofen and 
indomethacin in the medical management of PDA, there are important limitations to this 
study that should be addressed. First, the inclusion of infants by treatment rather than by 
diagnosis may include infants who received either ibuprofen or indomethacin for another 
purpose. By limiting to infants treated between postnatal days 2 and 14, we limited the 
population to those likely being treated for PDA and not another indication, but it is still 
possible that some patients without PDA remained in the study population. As only 25% of 
our patients <1000 g were included, and other studies have demonstrated incidence of PDA 
in this population as high as 57%, it is unlikely that many patients without PDA remained in 
our sample [32,33]. Second, we did not have access to echocardiographic data to confirm 
PDA closure, but instead used secondary predictors of poor outcomes including surgical 
ligation and mortality to demonstrate efficacy. Although this does not strictly define success 
of PDA closure, it does investigate clinically relevant persistent PDA, which is perhaps a 
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more important end point. Third, we did not have access to urine output or other factors that 
can be used to more completely assess renal function. Lastly, there is inherent variability in 
outcomes by NICU. We attempted to account for this variability by including fixed effects 
for NICU in our adjusted models. Nevertheless, such adjustments may not remove all 
sources of bias and our data should be interpreted with caution especially when compared to 
randomized controlled trials data.
In summary, in one of the largest studies to date to investigate the use of indomethacin and 
ibuprofen in the medical management of PDA, we found no major discernible safety 
differences between the 2 drugs. The optimal pharmaceutical agent for the medical 
management of PDA in premature infants remains uncertain.
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• We compared outcomes for indomethacin and ibuprofen for patent ductus 
arteriosus.
• There was extensive center-level variation in the use of each.
• There were no significant differences in effectiveness or safety.
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Study cohort. DOL, day of life.
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Ibuprofen and indomethacin use between 2006 and 2012.
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Variability in the use of ibuprofen and indomethacin among the 125 sites that treated 10 or 
more infants over the study period.
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Table 1
Demographics and baseline indicators of severity of illness of infants <28 weeks gestational age, by treatment 
group.
Ibuprofen (N = 1,177) Indomethacin (N = 5,172) p
Gestational age (weeks, continuous) 25 (24, 26) 25 (24, 26) 0.08
Gestational age (weeks, categorical) 0.42
 <25 346 (29%) 1,422 (27%)
 25–26 560 (48%) 2,530 (49%)
 27–28 271 (19%) 1,220 (24%)
Birth weight (g) 750 (640, 888) 770 (651, 910) <0.01
Birth weight <750 g 575 (49%) 2,319 (45%) 0.01
Small for gestational age 175 (15%) 653 (13%) 0.04
Male Sex 629 (53%) 2,631 (51%) 0.11
Race/ethnicity <0.01
 White 458 (40%) 2,343 (47%)
 Black 444 (39%) 1,387 (28%)
 Hispanic 192 (17%) 957 (19%)
 Other 48 (4.2%) 317 (6.3%)
Antenatal steroids 916 (78%) 4,258 (82%) <0.01
Age on day 1 of therapy (days) 4 (3, 7) 4 (3, 7) 0.11
>4 days of age on day 1 of therapy 694 (59%) 2,964 (57%) 0.30
Baseline creatinine on day 1 of therapy (mg/dL) 1.0 (0.8, 1.1) 0.9 (0.8, 1.1) <0.01
Baseline creatinine >1.0 mg/dL on day 1 of therapy 258 (22%) 892 (17%) <0.01
Mechanical ventilation on day 1 of therapy 866 (74%) 3,743 (73%) 0.22
FiO2 >21% on day 1 of therapy 694 (62%) 3,240 (66%) 0.03
Inotrope support on day 1 of therapy 211 (18%) 857 (17%) 0.26
Hydrocortisone therapy on day 1 of therapy 75 (6.4%) 130 (2.5%) <0.01
Continuous variables listed as median (interquartile range). Categorical variables listed as frequency (percentage).
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